CenterWatch, a leading publisher of clinical trials information for patients and professionals, announced today that it has launched a revamped version of its award-winning Clinical Trials Listing Service (CTLS) to better serve the public and patient communities.
CenterWatch
, a leading publisher of clinical trials information for patients and professionals, announced today that it has launched a revamped version of its award-winning
Clinical Trials Listing Service
(CTLS) to better serve the public and patient communities.
The new CTLS™ presents the largest international listing of phase I – IV clinical trials actively recruiting volunteers in simpler language, improved format, more advanced search capabilities and better navigation. CenterWatch solicited extensive feedback from patients to guide and direct the revamp effort.
“Patients and their advocates have long complained that online clinical trial registries and listings are too technical, difficult to understand and of questionable quality,” said Niki Eastley, CenterWatch’s senior manager of Internet Operations and Development. “We’re so pleased to make these enhancements with the patient at the center of our revamp efforts.”
As an independent publisher, CenterWatch’s clinical trial listing service aggregates information from a variety of sources including directly from research sponsors and from investigative sites making the CTLS™ the largest and most comprehensive listing of industry-funded clinical trials on the web today.
“We apply our editorial and quality standards to the listings in the CenterWatch service,” said Joan Chambers, Chief Operating Officer. “Most web sites show a small number of trials of variable quality. The CTLS™ is the go-to destination by patients and their advocates for the largest, highest quality, easiest-to-use clinical trial information available.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.